PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications • ...

Compass Therapeutics Inc. has announced a new drug candidate, CTX-10726, a novel tetravalent PD-1 x VEGF-A bispecific antibody.

NAYA Biosciences (NAYA) announced that it is expanding its bifunctional antibody pipeline to include a novel PD-1 x VEGF tetravalent ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and ...

Naya Biosciences Inc. has expanded its bifunctional antibody pipeline to include NY-500, a novel PD-1 x VEGF tetravalent bifunctional antibody for the treatment of hepatocellular carcinoma (HCC) and ...

Stifel Nicolaus analyst Stephen Willey has maintained their bullish stance on CMPX stock, giving a Buy rating today.Stay Ahead of the ...

The dengue vaccine market is on track for robust growth, with increasing global awareness, governmental support, and ...

PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications • NAYA aiming to initiate clinical trials in early 2026 SARASOTA, Fla.